A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

Background Checkpoint inhibitors can induce profound anticancer responses, but programmed cell death protein-1 (PD-1) inhibition monotherapy has shown minimal activity in prostate cancer. A published report showed that men with prostate cancer who were resistant to the second-generation androgen rec...

Full description

Bibliographic Details
Main Authors: Yiyi Chen, William L Redmond, Tomasz M Beer, Julie N Graff, Joshi J Alumkal, Rachel E Slottke, George V Thomas, Reid F Thompson, Mary A Wood, Emile Latour, Raymond C Bergan, Amy E Moran
Format: Article
Language:English
Published: BMJ Publishing Group 2020-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000642.full

Internet

https://jitc.bmj.com/content/8/2/e000642.full

Similar Items